Joseph Oakley

Dr. Joe Oakley is a molecular genetic pathologist who has specialized in biomarker development across multiple therapeutic areas and with nearly every modality of assay imaginable, from circulating tumor cells to machine learning image analysis of digital pathology images, to more routine immunohistochemistry and genomic mutation and expression analysis.  For the past 8 years, Dr. Oakley worked in the Clinical Diagnostic Laboratory of Eli Lilly and Company, developing biomarker assays for pre-clinical and clinical stage molecules in areas ranging from immunology and autoimmune to oncology and infectious disease.  Most recently, as an Associate Vice President—Medical at Eli Lilly, Dr. Oakley ran the diagnostic testing for COVID that supported the Indiana State Department of Health with direct public health testing, as well as the emergency use authorization of all three of Eli Lilly’s SARS-CoV-2 targeted monoclonal antibody therapies plus the emergency use authorization of baricitinib in the treatment of COVID.Oncology is Dr. Oakley’s first love, however, and the opportunity to join Paige as Medical Director of Biomarker Development to explore advanced phenotypic analysis by machine learning with a leader in digital pathology was too good to pass up.  Since May of 2022, Dr. Oakley has been working with Paige to leverage machine learning and artificial intelligence to find new complements to existing biomarker strategies with digital image analysis, as a way to accelerate personalization of oncology treatment.